ID

45813

Descripción

Principal Investigator: Leslie G. Biesecker, MD, National Institutes of Health, Bethesda, MD, USA MeSH: Atherosclerosis https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000971 ClinSeq is a pilot project to investigate the use of whole-genome sequencing as a tool for clinical research. By piloting the acquisition of large amounts of DNA sequence data from individual human subjects, we are fostering the development of hypothesis-generating approaches for performing research in genomic medicine, including the exploration of issues related to the genetic architecture of disease, implementation of genomic technology, informed consent, disclosure of genetic information, and archiving, analyzing, and displaying sequence data. In the initial phase of ClinSeq, we are enrolling roughly 1000 participants; the evaluation of each includes obtaining a detailed family and medical history, as well as a clinical evaluation. The participants are being consented broadly for research on many traits and for whole-genome sequencing. Initially, Sanger-based sequencing of 300-400 genes thought to be relevant to atherosclerosis is being performed, with the resulting data analyzed for rare, high-penetrance variants associated with specific clinical traits. The participants are also being consented to allow the contact of family members for additional studies of sequence variants to explore their potential association with specific phenotypes. Here, we present the general considerations in designing ClinSeq, preliminary results based on the generation of an initial 826 Mb of sequence data, the findings for several genes that serve as positive controls for the project, and our views about the potential implications of ClinSeq. The early experiences with ClinSeq illustrate how large-scale medical sequencing can be a practical, productive, and critical component of research in genomic medicine. Reprinted from Genome Res. 2009 Sep; 19(9): 1665-1674, with permission from Genome Research, PMID: 19602640.

Link

dbGaP study = phs000971

Palabras clave

  1. 29/6/23 29/6/23 - Simon Heim
Titular de derechos de autor

Leslie G. Biesecker, MD, National Institutes of Health, Bethesda, MD, USA

Subido en

29 de junio de 2023

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

dbGaP phs000971 The ClinSeq Project: Piloting Large-Scale Genome Sequencing for Research in Genomic Medicine

Eligibility Criteria

Inclusion and exclusion criteria
Descripción

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
ClinSeq participants are being selected to represent the spectrum of atherosclerotic heart disease using the Framingham score (Wilson et al. 1998, PMID: 9603539) to balance accrual. The accrual target is three groups of 250 participants each who have a Framingham 10-yr coronary artery disease (CAD) risk of <5%, 5%-10%, and >10%, respectively, and an additional group of 250 participants who have a diagnosis of CAD based on a history of a myocardial infarction, coronary artery bypass graft surgery, stent placement, or other revascularization procedure. This accrual strategy was implemented so that the cohort would be enriched for detectable coronary atherosclerosis, as measured by computed tomography.
Descripción

ClinSeq participants are being selected to represent the spectrum of atherosclerotic heart disease using the Framingham score (Wilson et al. 1998, PMID: 9603539) to balance accrual. The accrual target is three groups of 250 participants each who have a Framingham 10-yr coronary artery disease (CAD) risk of <5%, 5%-10%, and >10%, respectively, and an additional group of 250 participants who have a diagnosis of CAD based on a history of a myocardial infarction, coronary artery bypass graft surgery, stent placement, or other revascularization procedure. This accrual strategy was implemented so that the cohort would be enriched for detectable coronary atherosclerosis, as measured by computed tomography.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0679646
UMLS CUI [1,2]
C1882932
UMLS CUI [1,3]
C2827424
UMLS CUI [1,4]
C0010054
UMLS CUI [1,5]
C5442395
UMLS CUI [1,6]
C1510756
UMLS CUI [2,1]
C0441833
UMLS CUI [2,2]
C5442395
UMLS CUI [2,3]
C1956346
UMLS CUI [2,4]
C0011900
UMLS CUI [2,5]
C0262926
UMLS CUI [2,6]
C0027051
UMLS CUI [2,7]
C4699471
UMLS CUI [2,8]
C2348535
UMLS CUI [2,9]
C5244011
UMLS CUI [3,1]
C1510756
UMLS CUI [3,2]
C0010054
UMLS CUI [3,3]
C3830527
UMLS CUI [3,4]
C0040405

Similar models

Eligibility Criteria

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
ClinSeq participants are being selected to represent the spectrum of atherosclerotic heart disease using the Framingham score (Wilson et al. 1998, PMID: 9603539) to balance accrual. The accrual target is three groups of 250 participants each who have a Framingham 10-yr coronary artery disease (CAD) risk of <5%, 5%-10%, and >10%, respectively, and an additional group of 250 participants who have a diagnosis of CAD based on a history of a myocardial infarction, coronary artery bypass graft surgery, stent placement, or other revascularization procedure. This accrual strategy was implemented so that the cohort would be enriched for detectable coronary atherosclerosis, as measured by computed tomography.
Item
ClinSeq participants are being selected to represent the spectrum of atherosclerotic heart disease using the Framingham score (Wilson et al. 1998, PMID: 9603539) to balance accrual. The accrual target is three groups of 250 participants each who have a Framingham 10-yr coronary artery disease (CAD) risk of <5%, 5%-10%, and >10%, respectively, and an additional group of 250 participants who have a diagnosis of CAD based on a history of a myocardial infarction, coronary artery bypass graft surgery, stent placement, or other revascularization procedure. This accrual strategy was implemented so that the cohort would be enriched for detectable coronary atherosclerosis, as measured by computed tomography.
boolean
C0679646 (UMLS CUI [1,1])
C1882932 (UMLS CUI [1,2])
C2827424 (UMLS CUI [1,3])
C0010054 (UMLS CUI [1,4])
C5442395 (UMLS CUI [1,5])
C1510756 (UMLS CUI [1,6])
C0441833 (UMLS CUI [2,1])
C5442395 (UMLS CUI [2,2])
C1956346 (UMLS CUI [2,3])
C0011900 (UMLS CUI [2,4])
C0262926 (UMLS CUI [2,5])
C0027051 (UMLS CUI [2,6])
C4699471 (UMLS CUI [2,7])
C2348535 (UMLS CUI [2,8])
C5244011 (UMLS CUI [2,9])
C1510756 (UMLS CUI [3,1])
C0010054 (UMLS CUI [3,2])
C3830527 (UMLS CUI [3,3])
C0040405 (UMLS CUI [3,4])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial